MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3951
+0.0153
+4.03%
After Hours: 0.3900 -0.0051 -1.29% 19:55 07/14 EDT
OPEN
0.3900
PREV CLOSE
0.3798
HIGH
0.4000
LOW
0.3700
VOLUME
3.72M
TURNOVER
--
52 WEEK HIGH
2.510
52 WEEK LOW
0.2257
MARKET CAP
18.17M
P/E (TTM)
-0.2913
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACHV stock price target is 4.667 with a high estimate of 10.00 and a low estimate of 2.000.

EPS

ACHV News

More
ACHV: RAUORA: Cytisinicline's Superior Side Effect Profile
By John Vandermosten, CFA NASDAQ:ACHV
Benzinga · 06/30 18:11
ACHV: RAUORA: Cytisiniclines Superior Side Effect Profile
Zacks Small Cap Research · 06/30 14:33
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
PR Newswire · 06/29 13:35
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
CNW Group · 06/29 13:30
Achieve Life Sciences to raise $6M
Seeking Alpha - Article · 06/29 12:44
Achieve Announces Successful Results From Investigator-Initiated RAUORA Head-To-Head Non-Inferiority Clinical Trial Comparing Cytisinicline And Chantix As A Treatment To Quit Smoking
Cytisinicline demonstrated quit rates at least as effective as varenicline Participants on cytisinicline experienced significantly fewer side effects than those on varenicline SEATTLE and VANCOUVER, BC, June 29,
Benzinga · 06/29 12:32
Hedge Funds Nibbling On Achieve Life Sciences, Inc. (ACHV)
Insider Monkey · 06/05 19:49
ACHV: When Quitting Gets You to the Finish Line
Zacks Small Cap Research · 05/29 10:54

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About ACHV

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
More

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.